DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

Venous Thromboembolism - 2013

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The impending expansion of the treatment labels of the four nonmonitored, fixed-dose oral anticoagulants into the treatment and secondary prophylaxis of VTE will address the need for more-convenient alternatives to current standards of care, and these agents will drive market growth during the forecast period. However, opportunities remain in other underserved VTE indications, including primary prophylaxis of VTE in acute medically ill and ambulatory cancer patients.

Questions Answered in This Report:

  • The oral anticoagulant rivaroxaban (Bayer/Janssen’s Xarelto) is the first of the novel agents to gain approval for the acute treatment and secondary prophylaxis of VTE, with dabigatran etexilate (Boehringer Ingelheim’s Pradaxa), apixaban (Bristol-Myers Squibb/Pfizer’s Eliquis), and edoxaban (Daiichi Sankyo’s Lixiana) expected to follow soon. How do thought leaders perceive each of these drugs and their differentiating features? How will uptake of these agents in the market impact on current market-leading therapies? Which agents will be most successful and why?

  • The VTE primary prophylaxis market encompasses several different patient populations, with the novel oral anticoagulants only gaining approval in the orthopedic surgery setting. What lessons can be learned from negative clinical trial results in VTE primary prophylaxis populations outside of the orthopedic surgery setting? Which patient subpopulations have the greatest remaining unmet need and commercial potential?

  • The pipeline of new VTE therapies appears relatively bare in the near term, following recent anticoagulant drug approvals and drug discontinuations. However, exciting developments are being made for new therapeutic targets. What do thought leaders think of these alternative approaches? Have there been any recent improvements in the understanding of VTE disease pathophysiology and discoveries of potential new drug targets?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 23 country-specific interviews with thought leaders.

Epidemiology: Number of DVT events; number of PE events; number of hospitalization events (orthopedic surgery, major non-orthopedic surgery, minor nonorthopedic surgery, nonsurgical) eligible for VTE acute primary prophylaxis; number of prevalent cases of cancer patients eligible for VTE primary prophylaxis.

Population segments in market forecast: Primary prophylaxis indications (major orthopedic surgery, non-orthopedic surgery, nonsurgical patients, cancer patients eligible for prophylaxis); acute DVT treatment and secondary prophylaxis; acute PE treatment and secondary prophylaxis.

Emerging therapies: Phase II: 1 drug; Phase III/preregistration/registration: 6 drugs. Coverage of select preclinical and Phase I products.

Market forecast features: Using a patient-based model, we forecast drug sales for two market segments: for VTE acute treatment/secondary prophylaxis and VTE primary prophylaxis through 2022.